Accenture has invested in Ryght AI to help life sciences companies rethink how clinical research is planned and delivered. The deal, made through Accenture Ventures, focuses on one goal: getting new treatments to patients faster by removing friction from clinical trials.
Trials are becoming more complex, with site selection and patient enrollment causing costly delays. Ryght AI tackles this through its AI Site Twin platform, which creates live digital models of research sites using performance history, patient data, and operational metrics. This allows sponsors and CROs to choose the right sites faster, predict enrollment more accurately, and launch trials with fewer delays.
By combining Ryght AI’s agentic AI platform with Accenture’s industry and data-engineering expertise, the partnership targets three critical stages of drug development: feasibility, site selection, and recruitment.
Accenture says generative and agentic AI are reshaping the foundations of clinical research, while Ryght AI sees the collaboration as a way to scale its technology globally and shorten the path from discovery to treatment. The investment amount was not disclosed.
Related News